Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Today Michigan.
Press releases published on September 3, 2025
Migraine and Back-to-School: Experts Share Tips to Reduce Triggers and Support Students
GlobeNewswire
·
September 3, 2025
Providence, RI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- As the school year begins, the Association of Migraine Disorders (AMD) is highlighting the challenges students with migraine face during the back-to-school transition. Returning to the classroom means …
GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 3, 2025
Live webcast presentation with CEO, Dr. Marc Hertz, on September 9th at 3:00 PM ET LA JOLLA, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of …
Artelo Biosciences Announces Positive Interim Phase 2 CAReS Results for the Treatment of Cancer Anorexia-Cachexia Syndrome (CACS)
GlobeNewswire
·
September 3, 2025
Catalyst for Advancing Discussions with Pharmaceutical Companies that have Expressed Interest in ART27.13 for CACS Consistent Improvements in Weight Gain, Lean Body Mass, and Activity were Observed Across Treated Patients including +6.4% Mean Weight Gain …
Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)
GlobeNewswire
·
September 3, 2025
ISELIN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on optimizing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it will present at …
Journey Medical Corporation to Participate in September 2025 Investor Conferences
GlobeNewswire
·
September 3, 2025
SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“ …
PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
GlobeNewswire
·
September 3, 2025
PETACH TIKVA, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that senior management will participate in the upcoming …
Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series
GlobeNewswire
·
September 3, 2025
Live moderated webcast on Thursday, September 4th at 4:00 PM ET Access the event here BOSTON and LONDON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload …
Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule
GlobeNewswire
·
September 3, 2025
GLEN ALLEN, Va., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related …
CDT Board Authorizes Adoption of Cryptocurrency Treasury Reserve Strategy
GlobeNewswire
·
September 3, 2025
NAPLES, Fla. and CAMBRIDGE, United Kingdom, Sept. 03, 2025 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) ("CDT" or the "Company") today announced that, following its strategic review of the cryptocurrency and stablecoin market, engagement with third- …
Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation
GlobeNewswire
·
September 3, 2025
Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved …
Coherus Oncology to Participate in Upcoming Investor Conferences
GlobeNewswire
·
September 3, 2025
REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025 Global Healthcare Conference in New York, …
Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study
GlobeNewswire
·
September 3, 2025
New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean 5.08 reduction on the VAS pain scale, in patients with severe pancreatic cancer pain 100% of responders (n=7) 1 showed zero …
Vivos Inc Files Critical Patent For Hydrogel Electron Beam Sterilization
GlobeNewswire
·
September 3, 2025
Kennewick, WA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc filed a provisional patent No.: 63/873,014 - STERILE THERMOGELS Vivos Inc. is pleased to announce the successful validation of a new electron beam (E-Beam) sterilization …
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025
GlobeNewswire
·
September 3, 2025
THE WOODLANDS, Texas, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced data from a study of patients describing the physical and psychological impact of diabetic peripheral neuropathic pain (DPNP), despite …
Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio
GlobeNewswire
·
September 3, 2025
SARASOTA, FL, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that IP Australia (the Australian Patent …
United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use
GlobeNewswire
·
September 3, 2025
10-minute home test detects early kidney damage in diabetic and hypertensive patients Hypertension affects roughly one-third of adults in the UAE Diabetes impacts approximately one in four UAE nationals IRVINE, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- …
Assertio to Participate in the HC Wainwright and Lake Street Conferences in September 2025
GlobeNewswire
·
September 3, 2025
LAKE FOREST, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT) announced that members of its management team will host investor meetings at two investor conferences in New York City during …
Biotricity and B-Secur Target the Consumer Wearables Market with Expansion of Next-Gen Cardiac Monitoring Platform
GlobeNewswire
·
September 3, 2025
REDWOOD CITY, Calif./BELFAST, Northern Ireland, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY), an innovative medical technology company specializing in remote cardiac monitoring solutions, and B-Secur, a leader in ECG algorithm and …
Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research
GlobeNewswire
·
September 3, 2025
FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the acceptance …
NRx Pharmaceuticals (NASDAQ:NRXP) to Participate in a Fireside Chat at H.C. Wainwright's 27th Annual Global Investment Conference on Monday, September 8th
GlobeNewswire
·
September 3, 2025
WILMINGTON, Del., Sept. 03, 2025 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional …